Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05897320 · ClinicalTrials.gov registry record · Phase 3

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

A Phase 3 study of Episodic Migraine, sponsored by H. Lundbeck A/S.

Recruiting
Registry status
Phase 3
Development phase
315
Enrollment target
20
Study locations

NCT05897320: Recruiting Phase 3 study of Episodic Migraine, sponsored by H. Lundbeck A/S.

NCT05897320 is a Phase 3 study of Episodic Migraine that is actively recruiting participants, run by H. Lundbeck A/S. The registered enrollment target is 315 participants, below the 472-participant average among 13 other Episodic Migraine trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05897320, a Phase 3 study of Episodic Migraine, is actively recruiting participants, sponsored by H. Lundbeck A/S.

RECRUITING
Registry status
Phase 3
Development phase
315 participants
Enrollment target
20
Study locations

Study Summary

The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

Conditions Studied

Episodic Migraine

Interventions

  • DRUG Placebo
  • DRUG Eptinezumab

Study Locations (20)

Florida

  • Child Neurology of NW Florida - Gulf Breeze
  • AGA Clinical Trials - Hialeah
  • University of South Florida - 13330 USF Laurel Dr - Tampa

Ohio

  • Childrens Hospital Medical Center of Akron - Akron
  • Cincinnati Children's Hospital Medical Center - PIN - Cincinnati

Ciudad Autónoma de BuenosAires

  • Hospital Britanico de Buenos Aires - Barracas
  • Expertia S.A- Mautalén Salud e Investigación - Buenos Aires

Connecticut

  • Ki Health Partners LLC DBA New England Institute for Clinical Research - Stamford

Georgia

  • Clinical Integrative Research Center of Atlanta - Atlanta

Kentucky

  • University of Kentucky HealthCare (UKHC) Kentucky Clinic - Lexington

Maryland

  • University of Maryland School of Medicine - Baltimore

Michigan

  • Michigan Head Pain and Neurological Institute - Ann Arbor

Trial Details

FieldValue
Enrollment Target 315 participants
Start Date 2023-06-08
Est. Completion 2027-08-31
Phase Phase 3
H. Lundbeck A/S

72 total trials

What NCT05897320 shows while recruiting

NCT05897320 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 472-participant average among 13 other Episodic Migraine trials with a reported enrollment target (33% lower).

The record links to 1 condition, with Episodic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05897320 names 20 study sites across 16 states, led by Florida, Ohio, Ciudad Autónoma de BuenosAires.

Frequently Asked Questions

What is clinical trial NCT05897320 about?

NCT05897320 is a clinical study titled "A Study of Eptinezumab in Pediatric Participants With Episodic Migraine". The main goal of this trial is to learn whether eptinezumab helps reduce the number of days with episodic migraine in pediatric participants.

What is the current status of trial NCT05897320?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2023-06-08. Estimated completion is 2027-08-31.

What conditions does trial NCT05897320 study?

This clinical trial studies the following conditions: Episodic Migraine.

What interventions are being tested in trial NCT05897320?

The interventions under investigation include: Placebo (DRUG), Eptinezumab (DRUG).

Who is sponsoring clinical trial NCT05897320?

This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05897320 being conducted?

This trial has 20 study locations across Connecticut, Florida, Georgia, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Episodic Migraine

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05897320's enrollment target sits among peer trials

315 10th of 13 higher than 4 of 13 other Episodic Migraine trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Episodic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04812366 · 315 participants · Phase 2

    Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

  • NCT05101460 · 315 participants

    An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant

  • NCT06439082 · 315 participants · Phase 3

    A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

  • NCT06846320 · 315 participants · Phase 2

    Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05897320

Source: ClinicalTrials.gov NCT05897320, the US trial registry maintained by the National Library of Medicine. NCT05897320 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.